<?xml version="1.0" encoding="UTF-8"?>
<p id="Par118">In a randomized phase II trial, named SABR-COMET, a benefit in OS in the SBRT arm for the oligometastatic setting compared to palliative treatment was demonstrated (41 months vs 28 months) [
 <xref ref-type="bibr" rid="CR30">30</xref>]. In oligometastatic NSCLC, Gomez et al., that conducted a randomized phase II trial on oligometastatic NSCLC, reporting a significant PFS benefit with LCT (both radiotherapy or surgery) vs maintenance systemic therapy (14.4 months vs 4.4 months respectively). In oligometastic prostate cancer, HORRAD, STAMPEDE, STOMP and ORIOLE studies have shown encouraging results [
 <xref ref-type="bibr" rid="CR31">31</xref>–
 <xref ref-type="bibr" rid="CR34">34</xref>]. In oligometastatic breast cancer, Steven David et al. demonstrated that SABR is feasible, well tolerated and effective in selected patients with bone-only oligometastatic disease [
 <xref ref-type="bibr" rid="CR35">35</xref>].
</p>
